Seres Therapeutics Inc MCRB Stock Price & News

Seres Therapeutics Inc. shares cratered 78% in pre-market trade Friday after the company said interim phase 2 trial results for its colon infection treatment weren’t statistically significant. A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome.

The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Seres Therapeutics company info

The average rating score is and is based on 12 buy ratings, 0 hold ratings, and 1 sell ratings. The low in the last 52 weeks of Seres Therapeutics stock was 2.51. According to the current price, Seres Therapeutics is 233.53% away from the 52-week low. The high in the last 52 weeks of Seres Therapeutics stock was 9.47. According to the current price, Seres Therapeutics is 61.81% away from the 52-week high.

From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2023 is $131.81 million. The company’s revenue is forecast to grow by 1,749.20% over what it did in 2023. In conclusion, Seres Therapeutics Inc. has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”.

BECOME A MEMBER FOR ONLY $2 Get https://1investing.in/ to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals. Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.

Seres Therapeutics (MCRB) Stock Price & Analysis

We’d like to operation chart more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CompareMCRB’s historical performanceagainst its industry peers and the overall market. This means that this stock is suited as a new addition to your portfolio as trading bullish markets is always a lot easier.

• Wall Street analysts think that SER-109, at its peak, could rake in upwards of $750 million in annual sales.
• 7.38% of the outstanding shares of Seres Therapeutics have been sold short.
• The average trading volume of MCRB on April 11, 2023 was 989.35K shares.
• There is no information about the health of profitability of the underlying company in our sentiment score.
• Provide specific products and services to you, such as portfolio management or data aggregation.

Advisory accounts and services are provided by Webull Advisors LLC (also known as “Webull Advisors”). Webull Advisors is an Investment Advisor registered with and regulated by the SEC under the Investment Advisors Act of 1940. Trades in your Webull Advisors account are executed by Webull Financial LLC, a member of the Securities Investor Protection Corporation . That means your assets are protected up to $500,000 in value, including $250,000 in any cash awaiting reinvestment. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades.

Should You Sell Spectrum Pharmaceuticals Inc (SPPI) in Biotechnology Industry?

Click Here to get the full Stock Report for Seres Therapeutics Inc stock. Seres Therapeutics, Inc. is a microbiome therapeutics company. The Company is developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Building upon SER-109, it is developing microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Seres Therapeutics Inc. No upward and no downward comments were posted in the last 7 days.

The 13 analysts offering price forecasts for Seres Therapeutics have a median target of 18.85, with a high estimate of 46.00 and a low estimate of 7.00. The median estimate represents a 31.04 difference from the last price of 5.85. Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively.

Its specialists are interested in stocks that have been undervalued by different reasons. They are trying to find them, count their potential and bring them to their clients. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time.

• U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Tuesday.
• Here are some key insights as we drill into the specifics of these quality attributes.MCRB has a Quality Grade of C, ranking ahead of 46.12% of graded US stocks.
• According to the issued ratings of 5 analysts in the last year, the consensus rating for Seres Therapeutics stock is Buy based on the current 5 buy ratings for MCRB.
• Chardan Capital Markets gave a rating of “Buy” to MCRB, setting the target price at $30 in the report published on March 05th of the previous year.
• The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters.

The value of securities may fluctuate and as a result, clients may lose more than their original investment. The past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss in a down market. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing.

Seres Therapeutics News

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

The company’s lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection . It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infecti… Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends. Seres Therapeutics has been rated by Canaccord Genuity Group, Chardan Capital, and HC Wainwright in the past 90 days. Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat’s FREE daily newsletter. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services.

This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark. The average estimate suggests sales will likely up by 20.60% this quarter compared to what was recorded in the comparable quarter last year.